Shen Ling Bai Zhu San was found to inhibit inflammatory damage in nonalcoholic fatty liver disease, thus offering potential as a preventive and therapeutic treatment.
In the study, rats were put on a high-fat diet, with or without the addition of Shenling Baizhu powder or probiotics. Assessments were made at week 16, using an echo magnetic resonance imaging analyser to examine body composition, a micro-computed tomography imaging system to measure whole body and liver fat, and a laser perfusion imager to study liver microcirculation. After this, the rats were sacrificed and biochemical markers in the blood as well as liver ultrastructure were evaluated. The expression of proteins associated with liver inflammatory signaling pathways were scrutinized via Western blot analysis alongside a high-throughput screening of 29 relevant inflammatory factors in liver tissue.
The results indicated that supplementing with Shenling Baizhu powder reduced body weight, serum free fatty acid, and insulin resistance. It also improved liver microcirculation and ultrastructural abnormalities. Quantitative analyses manifested that the treatment lowered fat mass and visceral fat. Moreover, the powder reduced the expression of certain inflammatory signaling pathway-related proteins and modified the expression levels of some inflammatory cytokines found in liver tissues. Thus, indicating that Shenling Baizhu powder could inhibit the activation of inflammatory agents and suppress related expressions, making it potentially beneficial for the prevention and treatment of inflammatory damage and associated diseases.